We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

167 hedge funds and large institutions have $1.94B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 59 increasing their positions, 56 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $13.7M | Put options by funds: $8.54M

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

5% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 56

8% less funds holding

Funds holding: 182167 (-15)

21% less capital invested

Capital invested by funds: $2.47B → $1.94B (-$527M)

39% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 38

Holders
167
Holders Change
-15
Holders Change %
-8.24%
% of All Funds
2.93%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.11%
New
23
Increased
59
Reduced
56
Closed
38
Calls
$13.7M
Puts
$8.54M
Net Calls
+$5.2M
Net Calls Change
-$5.03M
Name Holding Trade Value Shares
Change
Change in
Stake
BNP Paribas Asset Management
26
BNP Paribas Asset Management
France
$17M +$17.7M +379,256 New
NNPTE
27
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Poland
$15.6M +$150K +3,225 +0.9%
EP
28
Eversept Partners
New York
$15.5M +$4.63M +99,477 +40%
KCM
29
Kornitzer Capital Management
Kansas
$15.5M +$4.28M +91,950 +36%
SCM
30
Suvretta Capital Management
New York
$15.1M +$15.7M +336,808 New
Norges Bank
31
Norges Bank
Norway
$14.6M -$5.08M -109,014 -25%
EMFAT
32
Emerald Mutual Fund Advisers Trust
Pennsylvania
$14.3M
TCM
33
Tekla Capital Management
Massachusetts
$13.8M +$11.5M +246,333 +401%
FCM
34
Farallon Capital Management
California
$13.5M
EA
35
Emerald Advisers
Pennsylvania
$12.8M -$1.83M -39,280 -12%
UBS AM
36
UBS AM
Illinois
$12.8M -$4.77M -102,410 -26%
Charles Schwab
37
Charles Schwab
California
$12.1M +$519K +11,151 +4%
Capital World Investors
38
Capital World Investors
California
$12.1M
American Century Companies
39
American Century Companies
Missouri
$11.8M +$2.26M +48,557 +23%
Hudson Bay Capital Management
40
Hudson Bay Capital Management
Connecticut
$10.3M +$1.16M +25,000 +12%
HRCM
41
Hood River Capital Management
Florida
$10.3M -$9.15M -196,621 -46%
OM
42
Opaleye Management
Massachusetts
$9.95M
CS
43
Candriam SCA
Luxembourg
$9.68M +$885 +19 +0%
Wellington Management Group
44
Wellington Management Group
Massachusetts
$9.08M -$240K -5,146 -2%
GKIM
45
GW&K Investment Management
Massachusetts
$9.06M +$9.41M +202,078 New
AG
46
Artal Group
Luxembourg
$8.97M -$14M -300,000 -60%
CAM
47
Cormorant Asset Management
Massachusetts
$8.97M
Bank of New York Mellon
48
Bank of New York Mellon
New York
$8.14M -$285K -6,126 -3%
Deutsche Bank
49
Deutsche Bank
Germany
$8.04M -$94K -2,019 -1%
Alyeska Investment Group
50
Alyeska Investment Group
Illinois
$7.53M +$2.39M +51,339 +44%

DCPH Hedge Fund Activity: Q1 2021 in Review

167 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2021, worth a combined $1.94B — down 21% from $2.47B a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of DCPH and 23 opened new positions — a net loss of 15 holders — while 56 trimmed existing stakes and 59 added.

The largest buyer was Consonance Capital Management, adding an estimated $23.7M. The largest seller was Fidelity Investments, cutting an estimated $30.2M.

  • 167 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2021, down from 182 in Q4 2020.
  • Funds reported $1.94B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2021, down 21% quarter-over-quarter.
  • 23 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 38 closed out, a net change of -15 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Consonance Capital Management, an estimated $23.7M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2021 was Fidelity Investments, an estimated $30.2M sold.

Based on aggregated 13F filings for Q1 2021.